1. null
    Bikash Baral, 2017 CrossRef
  2. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice
    Ruo-lin Zhao et al, 2018, Journal of Ethnopharmacology CrossRef
  3. Molecular bases of the poor response of liver cancer to chemotherapy.
    Jose J G Marin et al, 2018, Clin Res Hepatol Gastroenterol CrossRef
  4. Comparative study of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 3D (spheroids) cell cultures models
    Andreia S. Barros et al, 2018, International Journal of Pharmaceutics CrossRef
  5. Establishment of 2D Cell Cultures Derived From 3D MCF-7 Spheroids Displaying a Doxorubicin Resistant Profile
    Ana S. Nunes et al, 2018, Biotechnol. J. CrossRef
  6. null
    José-Luis Ríos et al, 2015 CrossRef
  7. Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
    Qingmei Ye et al, 2019, Front. Oncol. CrossRef
  8. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
    María Paula Ceballos et al, 2019, CMC CrossRef
  9. null
    José-Luis Ríos et al, 2017 CrossRef
  10. Ganoderiol F purified from Ganoderma leucocontextum retards cell cycle progression by inhibiting CDK4/CDK6
    Xiangmin Li et al, 2019, Cell Cycle CrossRef
  11. Models for Understanding Resistance to Chemotherapy in Liver Cancer
    Jose J. G. Marin et al, 2019, Cancers CrossRef
  12. null
    Zhiwei Qiu et al, 2019 CrossRef
  13. null
    Yu Sun et al, 2019 CrossRef
  14. Ganoderic acid A is the effective ingredient of Ganoderma triterpenes in retarding renal cyst development in polycystic kidney disease
    Jia Meng et al, 2020, Acta Pharmacol Sin CrossRef
  15. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells
    Yan Wen et al, 2017, Oncotarget CrossRef
  16. Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells
    Xiangmin Li et al, 2016, Oncotarget CrossRef
  17. Herb–drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review
    Chun Sing Lam et al, 2020, Chin Med CrossRef
  18. The Versatile Functions of G. Lucidum Polysaccharides and G. Lucidum Triterpenes in Cancer Radiotherapy and Chemotherapy
    Jing Xu et al, 2021, CMAR CrossRef
  19. Valorisation of biomass and diaper waste into a sustainable production of the medical mushroom Lingzhi Ganoderma lucidum
    Shing Ching Khoo et al, 2022, Chemosphere CrossRef
  20. Current Advancements in Antitumor Properties and Mechanisms of Medicinal Components in Edible Mushrooms
    Jing Xu et al, 2022, Nutrients CrossRef
  21. Deciphering the chemical composition of Ganoderma lucidum from different geographical origins by mass spectrometry molecular networking coupled with multivariate analysis
    Jia Liu et al, 2022, Biomedical Chromatography CrossRef
  22. Identifying Bioactive Ingredients and Antioxidant Activities of Wild Sanghuangporus Species of Medicinal Fungi
    Hao Wang et al, 2023, JoF CrossRef
  23. Integrating in Silico and In Vitro Studies to Screen Anti-Staphylococcus aureus Activity From Vietnamese Ganoderma multiplicatum and Ganoderma sinense
    Trang Thi Thu Nguyen et al, 2023, Natural Product Communications CrossRef
  24. Ganoderma lucidum: A comprehensive review of phytochemistry, efficacy, safety and clinical study
    Sijia Wu et al, 2023 CrossRef
  25. A network pharmacology integrated serum pharmacochemistry strategy for uncovering efficacy of YXC on hepatocellular carcinoma
    Ting-ting Zhou et al, 2024, Journal of Ethnopharmacology CrossRef
  26. A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer
    Ting Ye et al, 2023, Chin Med CrossRef
  27. null
    Eswara Rao Puppala et al, 2023 CrossRef